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Abstract
Background:Genome-wide association studies have identified
approximately 100 common genetic variants associated with
breast cancer risk, the majority of which were discovered in
women of European ancestry. Because of different patterns of
linkage disequilibrium, many of these genetic markers may not
represent signals in populations of African ancestry.
Methods: We tested 74 breast cancer risk variants and con-
ducted fine-mapping of these susceptibility regions in 6,522
breast cancer cases and 7,643 controls of African ancestry from
three genetic consortia (AABC, AMBER, and ROOT).
Results: Fifty-four of the 74 variants (73%) were found to
have ORs that were directionally consistent with those previ-
ously reported, of which 12 were nominally statistically signif-
icant (P < 0.05). Through fine-mapping, in six regions (3p24,
12p11, 14q13, 16q12/FTO, 16q23, 19p13), we observed seven
markers that better represent the underlying risk variant for
overall breast cancer or breast cancer subtypes, whereas in
another two regions (11q13, 16q12/TOX3), we identified sug-
gestive evidence of signals that are independent of the reported
index variant. Overlapping chromatin features and regulatory
elements suggest that many of the risk alleles lie in regions with
biological functionality.
Conclusions: Through fine-mapping of known susceptibility
regions, we have revealed alleles that better characterize breast
cancer risk in women of African ancestry.
Impact: The risk alleles identified represent genetic markers for
modeling and stratifying breast cancer risk in women of African
ancestry. Cancer Epidemiol Biomarkers Prev; 26(7); 1016–26.2017 AACR.
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Introduction
Genome-wide association (GWAS) and large-scale fine-
mapping studies have led to the identification of >100 breast
cancer susceptibility loci that are estimated to explain approx-
imately 20% of the 2-fold familial risk of breast cancer in
women of European descendant (1–13). For populations of
African ancestry, where the span of linkage disequilibrium (LD)
has been shortened by recombination events (more genera-
tions), a weaker correlation between an "index" marker (from
GWAS in Asian and European ancestry populations) and bio-
logically relevant risk variants is expected. As a consequence,
the index marker might not accurately capture the risk associ-
ated with the biologically functional variant in African ancestry
populations. Comprehensive testing in a large African ancestry
sample is needed to identify a set of markers that better capture
risk associated with the functional allele at known risk regions,
which is an important prerequisite for constructing genetic risk
models for this population. Previous fine-mapping investiga-
tions in women of African ancestry have been limited in size,
with the largest study including 3,016 breast cancer cases and
2,745 controls and having 80% power to detect reported effect
sizes for only 10 of 72 variants examined (1–15).
To obtain greater statistical power for fine-mapping of known
breast cancer susceptibility regions, we combined genotype and
imputed data for 6,522 breast cancer cases and 7,643 controls
from three large consortia of African ancestry breast cancer—the
African American Breast Cancer GWAS Consortium (AABC;
ref. 16), the African American Breast Cancer Epidemiology and
Risk Consortium (AMBER; refs. 17, 18), and the Genome-Wide
Association Study of Breast Cancer in the African Diaspora Con-
sortium (ROOT; ref. 19). In addition to testing the reported index
variants from previous GWAS, we conducted association analyses
and functional annotation across each region in search ofmarkers
that might best define breast cancer risk in women of African
ancestry.
Materials and Methods
Studies
The genetic data included in this analysis were from three
consortia of breast cancer in women of African ancestry (AABC,
AMBER, and ROOT). For this analysis, the African American
Breast Cancer Consortium (AABC) included seven epidemiologic
studies: TheMultiethnic Cohort study (MEC), 734/1,003; The Los
Angeles component of The Women's Contraceptive and Repro-
ductive Experiences (CARE) Study, 380/224; The San Francisco
Bay Area Breast Cancer Study (SFBCS), 172/23; The Northern
California site of the Breast Cancer Family Registry (NC-BCFR),
440/53; The Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO) Cohort, 64/133; The Nashville Breast
Health Study (NBHS), 310/186; and The Wake Forest University
Breast Cancer Study (WFBC), 125/153). The current analysis
includes GWAS data for 2,225 invasive cases and 1,983 controls
from AABC (14). Although the Women's Circle of Health Study
(WCHS) and The Carolina Breast Cancer Study (CBCS) partici-
pated in AABC, samples from those studies are included as part of
the AMBER consortium described below.
The AMBER consortium (18) included three studies for a total
of 2,754 invasive breast cancer cases and 3,698 controls: the Black
Women's Health Study (BWHS; ref. 20; 752/2249); WCHS (681/
834; ref. 21); and CBCS (1321/615; ref. 22).
The ROOT consortium (19) included six studies and a total of
1,657 cases and 2,028 controls of African ancestry: The Nigerian
Breast Cancer Study (NBCS), 711/623; The Barbados National
Cancer Study (BNCS), 92/229; TheRacial Variability inGenotypic
Determinants of Breast Cancer Risk Study (RVGBC), 145/257; The
Baltimore Breast Cancer Study (BBCS), 95/102; The Chicago
Cancer Prone Study (CCPS), 394/387; and The Southern Com-
munity Cohort (SCCS), 220/430.
Genotyping and quality control
Genotyping inAABCwas conductedusing the IlluminaHuman
1M-Duo BeadChip as described in Chen and colleagues (14). The
ROOT samples were genotyped using the Illumina 2.5 M array
(23). Samples in AMBER were genotyped using an Illumina
Infinium custom160 K SNP array which included approximate-
ly 45,000 SNPs selected primarily for fine-mapping of known
breast cancer susceptibility regions.
Statistical analysis
Imputation in AABC and AMBER was conducted using
IMPUTE2 (24) to a cosmopolitan panel of all 1000 Genome
Project subjects (March 2012 release). IMPUTE2 (24) was also
used to impute the untyped SNPs in ROOT using a cosmopolitan
panel of all 1000 Genome Project subjects (October 2011
release). Imputed SNPs with imputation quality score > 0.7 and
aminor allele frequency >0.01 in each studywere used in thefine-
mapping analysis. We examined 74 risk variants for breast cancer
in 72 regions that had been reported at the time this study was
initiated (1–11). One additional variant, rs11571833 at chromo-
some 13q13, was not genotyped and could not be imputed in all
three studies; this variant had aminor allele frequency of 0.006 in
the 1000Genomes AFRpopulation. These 74 risk variants include
stronger markers than the index SNP found in GWAS as well as
independent signals discovered through subsequent fine-map-
ping studies (Supplementary Table S1; refs. 1, 3, 4, 8, 10, 11).
A total of 6,522 breast cancer cases (2,933 ERþ and 1,876 ER)
and 7,643 controls were included in the analysis. For each typed
and imputed SNP, ORs and 95% confidence intervals (95% CI)
were estimated using unconditional logistic regression adjusting
for age (at diagnosis for cases and age at the reference date for
controls), study, and the first 10 eigenvectors from a principal
components analysis (25). For each SNP that existed in all three
studies, we tested for allele dosage effects separately in each of the
three studies, applying a 1-degree-of-freedom Wald c2 trend test.
Results were then combined using inverse variance–weighted
fixed-effects meta-analysis, as implemented in METAL (26). We
tested for effect heterogeneity between studies using Cochran Q-
test as implemented in METAL. Power calculations were con-
ducted using Quanto (http://hydra.usc.edu/gxe/) using the OR in
previous GWAS and the allele frequency in African Americans.
To identify alleles thatmight capture thebiologically functional
variant at 70 of the known breast cancer risk regions, we searched
and tested LD proxies among the genotyped and imputed SNPs
that were correlated (r2 0.4) with the index SNP [within 250 kb
or larger if the index signal was contained within an LD block
(based on the D' statistic) of >250 kb] in European ancestry
populations, resulting in a total of 157,920 SNPs included in the
analysis. Two regions, 5p15 and 20q11, were excluded from fine-
mapping because the AABC sample was involved in the discovery
of the risk loci in these regions (27, 28). The GWAS arrays and
imputation in AAPC, AMBER, and ROOTprovided good coverage
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of common variation (>5%) in the fine-mapped regions in
African ancestry populations. For AABC, an average of 96% of
common SNPs with a MAF >5% in the phase III 1000 Genome
AFR population were tagged (at r2 > 0.8) by the genotyped and
imputed SNPs. For ROOT and AMBER, these averages were each
97%. For each study, the coverage was >90% for all regions, with
the exception of chromosome 1p11 (45% in each) and chromo-
some 6q25 in AMBER (82%).
Locus-specific significance levels were calculated as
described in Feng and colleagues, 2014 (ref. 15; Supplemen-
tary Table S2). More specifically, locus-specific significance
levels were calculated as 0.05 divided by the number of tag
SNPs in the African population (1000 Genomes, AFR, March
2012 Release) that capture (r2  0.8) all SNPs correlated with
the index signal in the European population (1000 Genomes,
EUR, March 2012 Release). To reduce false-positive signals, we
required the P value of all better markers to be less than 0.01.
In an attempt to eliminate minor fluctuations in P values for
correlated SNPs, we also required the P value to decrease by
more than one order of magnitude compared with the asso-
ciation with the index signal. If multiple variants satisfied the
above criterion in each region, only the most statistically
significant variant was reported.
We also tested for novel independent associations, focusing
on all genotyped and imputed SNPs in each region that were
uncorrelated with the index signal in European ancestry popu-
lations (r2 < 0.1), and applied a significance criterion of a¼ 5 
106 for defining suggestive novel associations, as used in prior
studies (14). This a is not as conservative as genome-wide
significance and is an approximation of the number of tests
to capture (at r2  0.8) common risk alleles across all regions.
To confirm independent associations, conditional analyses
were performed that included the index SNP or better marker
plus the most significant uncorrelated allele. The analysis was
first conducted in each separate study and then combined using
fixed-effects meta-analysis. Haplotype analysis on 16q12 was
conducted applying the "haplo.stats" package in R (http://
www.mayo.edu/research/labs/statistical-genetics-genetic-epide
miology/software).
The procedures described above were applied to the analysis of
overall breast cancer as well as in secondary analyses stratified by
ER status.
Functional annotations
We assessed whether any of the signals colocalized with 65
chromatin features that capture open chromatin regions and
regulatory elements across the genome in ERþ breast cancer
(MCF7, T47D, HCC1954), ER breast cancer (MDAMB231) and
normal breast (HMEC, Myoepithelial, Fibroblast, Luminal epi-
thelial) cells identified by the Coetzee Laboratory (29–31) or
obtained from the Encyclopedia of DNA Elements (ENCODE)
project (32) orNIHRoadmapEpigenomicsMappingConsortium
(REMC; refs. 33, 34). Enriched regions of chromatin features were
either called by using the Sole-search program (35) or obtained
from GEO databases (GSE35583, GSE32970, GSE35239,
GSE46074, GSE49651, GSE78913). To refine the genomic regu-
latory regions, chromatin state segmentation information built by
using a HiddenMarkovModel (HMM) inMCF7 andHMECwere
also included (36, 37).
We used motifbreakR (38) to search for transcription factor
motifs that bind to each variant (39–43). Chromatin features that
overlapped variants and motifs that significantly altered binding
(using the default setting with the score threshold, 0.9) are
summarized in Supplementary Table S3. We also included key
transcription factors for breast cancer such as FOXA1, GATA3,
and ESR1 ChIP-seq data in ERþ breast cancer cells (MCF7, T47D)
from the ENCODE project to examine the occupancy of tran-
scription factors in vitro at regulatory elements where variants
reside (32).
Results
Of the 74 breast cancer risk variants, 68 were also common in
women of African ancestry, with minor allele frequencies greater
than 0.05 in all three studies. Of these 68 variants, we had50%
and80%power (at P < 0.05) to detect previously reported effect
sizes for 51 and 36 variants, respectively. The ORs observed for 54
(73%) of the 74 SNPs were directionally consistent with those
previously reported (i.e., ORswere in the same direction), with 12
variants nominally statistically significant at P < 0.05 (Table 1;
Supplementary Table S1). Of the 61 SNPs that were directionally
consistent with previous GWAS findings and not replicated at P <
0.05 in this study, statistical power to detect the previously
reported effect size for overall breast cancer was 80% for 29
(48%) SNPs (Supplementary Table S1). Fifty-three (72%) var-
iants were positively associated with ERþ breast cancer (8 statis-
tically significant at P < 0.05) and 37 (50%) variants were
positively associated with ER disease (10 statistically significant
at P < 0.05) (Supplementary Table S4). Of the 7 variants that were
reported tobemore strongly associatedwith ER thanERþdisease
in European ancestry populations (rs6678914/1q32, rs4245739/
1q32, rs12710696/2p24, rs10069690/5p15, rs11075995/16q12,
rs67397200/19p13, rs2284378/20q11; refs. 2, 27, 28, 44), all were
positively associated with the risk of ER disease (3 at P < 0.05;
rs4245739, rs10069690, and rs67397200). Statistical power was
80% to detect the reported effect size with ER disease for 4 of
the 7 variants (Supplementary Table S4).
To identify markers at known risk regions that might better
define the index signals or serve as secondary, independent
signals, fine-mapping analysis was conducted at each of the 70
regions (excluding 5p15 and 20q11, see Materials and Methods).
Using region-specific thresholds, we observed associations of 7
markers with overall breast cancer or breast cancer subtypes at 6
regions (3p24, 12p11, 14q13, 16q12/FTO, 16q23, 19p13), while in
two regions (11q13 and 16q12), we observed suggestive evidence
of signals independent of the reported index variant (Supplemen-
tary Table S5). These regions are discussed below.
At 3p24, the index variant, rs4973768, was more strongly
associated with ER than ERþ disease in the initial GWAS (ERþ:
OR ¼ 1.06, ER: OR ¼ 1.12, Phet ¼ 0.022; ref. 7). Variant
rs2370946, located in the intron of theNEK10 gene, with enhanc-
er histone marks in ERþ breast cancer cells (i.e., HCC1954) and
155 kb from the index variant, rs4973768, was found statistically
significantly associated with ERþ breast cancer in women of
African ancestry (ERþ: OR ¼ 1.17, P ¼ 7.8  104; ER: OR ¼
1.11, P ¼ 0.058; Supplementary Figs. S1 and S2). Variant
rs2370946 is correlated with the index in European populations,
but not in African populations (EUR: r2 ¼ 0.66; AFR: r2 ¼ 0.01).
At 11q13, the same variant reported by Chen and colleagues
(rs609275:OR¼1.20,P¼1.0105; ref. 14)was identified as an
independent secondary signal in this region (Supplementary
Table S5). This variant was statistically significantly associated
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with overall breast cancer in women of African ancestry [OR ¼
1.13,P¼4.5106; r2with the index variant: 0.022 (EUR), 0.003
(AFR); Fig. 1; Supplementary Fig. S1]. The variant rs609275,
which resides in a gene desert region at 11q13, is located in a
breast-specific active enhancer found not only in normal breast
cells, but also breast cancer cells (both ERþ andER).Weobserved
that the motif of NR3C1 (a.k.a. GR, glucocorticoid receptor) is
disrupted by the SNP; NR3C1 is known to inhibit MAPK activa-
tion by inducing MAPK1, possibly influencing breast cancer cell
survival (ref. 45; Fig. 1; Supplementary Fig. S2).
At 12p11, the index variant, rs10771399, was statistically sig-
nificantly associated with both ERþ and ER breast cancer in the
initial GWAS (46). No significant association was observed with
overall breast cancer or breast cancer subtypes in women of
African ancestry. Fine-mapping of this region in our African
ancestry sample revealed two variants, rs73094066 and rs805510,
associated with overall and ERþ breast cancer, respectively
(rs73094066 for overall breast cancer: OR ¼ 1.11, P ¼ 0.0027;
rs805510 for ERþ disease: OR ¼ 1.11, P ¼ 0.0026). Both
rs73094066 and rs805510 are correlated with the index variant
(rs10771399) in European populations, but not in African popu-
lations (rs73094066: EUR r2 ¼ 0.447, AFR r2 ¼ 0.099; rs805510
EUR r2¼ 0.912, AFR r2¼ 0.005; Supplementary Fig. S1). A recent
fine-mapping study on 12p11 detected a better marker,
rs7297051, in Europeans (11). The better markers discovered in
our study were weakly correlated with rs7297051 in Europeans
(rs73094066: EUR r2¼ 0.084, AFR r2¼ 0.003; rs805510 EUR r2¼
0.303, AFR r2 ¼ 0.004). The variants rs73094066 and rs805510
are near enhancer histonemarks, both found in breast cancer and
normal breast cells, in the 12p11.22 gene desert region (Supple-
mentary Fig. S2).
At 14q13, the index variant, rs2236007, was reported to be
more strongly associated with ERþ than ER breast cancer in
the initial GWAS (ERþ: OR ¼ 1.10, P ¼1.9  1010; ER: OR ¼
1.04, P¼ 0.081, Phet¼ 0.015; Supplementary Table S4; ref. 7). No
association with the index variant could be detected in women of
African ancestry (ERþ: OR¼ 0.98, P¼ 0.72; ER: OR¼ 0.94, P¼
0.39). Through fine-mapping, the association with the most
statistically significant P value was observed with rs73258644
andERþdisease (ERþ:OR¼1.43,P¼1.0106; ER:OR¼1.02,
P ¼ 0.82). rs73258644 is a perfect proxy for rs17104923, which
we previously reported in AABC as a potential independent signal
(r2¼ 1 in EUR and AFR), and shows no correlation with the index
variant rs2236007 (EUR r2 ¼ 0.008; AFR r2 ¼ 0.002). Among
markers correlated with the index variant, the strongest associa-
tion was observed with rs12883049 and ERþ disease (OR¼ 1.19,
P¼5.6105; Supplementary Fig. S1). This variant, rs12883049,
is located in the intron of PAX9with enhancer histone marks and
open chromatin marks in all breast cell lines, suggesting an
important role of this variant (Fig. 2; Supplementary Fig. S2).
We also found that themotif of TFAP4 (a.k.a. AP4) is disrupted by
the SNP. AP4 is involved in the cell cycle and also activates cell
migration and epithelial–mesenchymal transition in breast can-
cer (47, 48). This variant iswell correlatedwith the index variant in
Europeans (r2¼ 0.82), but not inwomen of African ancestry (r2¼
0.01). Variants rs73258644 and rs12883049 are modestly corre-
lated (r2 ¼ 0.35) and only rs73258644 remains statistically
significant in conditional analyses with rs12883049 (P ¼ 8.8 
104) which suggests that rs73258644 is the best marker in the
region relevant to women of African ancestry (Supplementary
Table S6).
At 16q12/TOX3, the index variant rs3803662 was identified
initially in association with ERþ disease (12). This variant was not
associated with breast cancer subtypes in women of African
ancestry (Supplementary Table S4). Our fine-mapping analysis
of this region revealed a risk variant in the intron of TOX3,
rs35850695 (r2¼ 0.89 in EUR), that wasmore strongly associated
with ERþ breast cancer (ERþ: OR¼ 1.25, P¼ 2.4 105; ER–: OR
¼ 1.07, P ¼ 0.33; Phet ¼ 0.033; Supplementary Table S5).
However, themost statistically significantly associated risk variant
in this region was rs3104791, which is located in the intron of
long noncoding RNA (lncRNA), LINC00918 (OR ¼ 1.18 for ERþ
disease, P ¼ 1.8  106; Supplementary Fig. S2). This variant is
moderately correlatedwith the index (rs3803662) inbothwomen
of European and African ancestry (EUR: r2¼ 0.28; AFR r2¼ 0.20)
and is also moderately correlated with rs35850695 in Europeans,
but not in women of African ancestry (EUR: r2 ¼ 0.24; AFR r2 ¼
0.018). A second potentially independent signal, rs3112565, was
also noted (OR ¼ 1.19, P ¼ 2.3  105), which is a perfect proxy
(r2 ¼ 1 in AFR) for rs3112572 (14) and rs3104746 reported
previously (ref. 49; Supplementary Table S6). In conditional
analyses of these three signals, rs35850695 (P ¼ 5.2  105)
and rs3112565 (P¼ 0.0011) remained as independent signals for
ERþ disease, but not rs3104791 (P¼ 0.054; Supplementary Table
S6). Haplotypes containing the risk variant for rs3104791 were
statistically significantly associated with risk together with either
the risk alleles of rs3112565 and/or rs35850695, but not alone
(OR ¼ 1.03; P ¼ 0.54; Supplementary Table S6). The variant
rs35850695 is located in the intron of TOX3 gene, whereas the
variants rs3112565 and rs310479 are located in the intron of
LINC00918. The variant rs3112565 is also found in ERþ cancer–
specific enhancer regions, annotated by histonemarks, H3K4me1
and H3K27Ac (Supplementary Fig. S2).
At 16q12/FTO, two independent signals (rs17817449 and
rs11075995) were discovered to be associated with breast
cancer risk in previous GWAS and rs11075995 was identified
as an ER specific variant (7). In women of African ancestry,
rs17817449 showed a statistically significant association with
both overall breast cancer and ERþ disease (overall: OR ¼ 1.07,
P ¼ 0.012; ERþ: OR ¼ 1.08, P ¼ 0.029). We observed an
association with rs62048370, that was statistically significantly
and more strongly associated with ERþ breast cancer (overall:
OR ¼ 1.29, P ¼ 0.00032; ERþ: OR ¼ 1.59, P ¼ 3.0  106; ER:
OR ¼ 1.04, P ¼ 0.72). Variant rs62048370 is not correlated
with either of the index variants in European or African popu-
lations (rs17817449: EUR r2 < 0.001, AFR r2 ¼ 0.004;
rs11075995: EUR r2 < 0.001, AFR r2 ¼ 0.007; Supplementary
Fig. S1; Supplementary Table S5). This variant also overlaps
with enhancer histone marks in ERþ breast cancer and normal
breast cell lines, which are in close proximity to open chro-
matin regions in which transcription factors such as FOXA1,
GATA3, and ESR1 bind (Supplementary Fig. S2).
At 16q23, the index variant rs13329835 was reported to be
more strongly associatedwith ERþdisease in the initialGWAS (7).
Through fine-mapping, we identified another variant, rs9940301,
which is highly correlated with the index variant in Europeans
(r2 ¼ 0.84), and was statistically significantly associated with
ERþ breast cancer in women of African ancestry (OR ¼ 1.13,
P¼ 8.5 104; Supplementary Table S5; Supplementary Fig. S1).
The variant rs9940301 is in the intron of the CDYL2 gene, and
encodes a chromodomain protein, which interacts with histone
H3K9me3 (Supplementary Fig. S2; ref. 50).
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Figure 1.
Regional plot and genome browser view of 11q13. The chromosomal position (based on GRCh37) of SNPs on 11q13 against log10P values for overall breast
cancer is shown on the top plot. The blue arrow denotes the secondary signal rs609275. The purple circle denotes the index variant rs614367. SNPs surrounding the
index variant are colored to indicate the LD structure using pairwise r2 in reference to rs614367 from the May 2012 EUR panel of 1000 Genomes. The plots were
generated using LocusZoom (55). Genome browser views with epigenetic chromatin features in breast cells (MCF7, HCC1954, MDAMB231, HMEC) on 11q13 are
generated using the UCSC genome browser (56). Below is a magnified view of rs609275 with selected enhancer chromatin marks and DNA sequence of a
response element. The gray shading indicates the location of the variant rs609275.
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Figure 2.
Regional plot and genome browser view of 14q13. The chromosomal position (based on GRCh37) of SNPs on 14q13 against log10P values for ERþ breast
cancer is shown. The blue arrow denotes the signal rs73258644 and the red arrow denotes rs12883049, which is a better marker of the index signal. The purple
circle denotes the index variant rs2236007. SNPs surrounding the index variant are colored to indicate the LD structure using pairwise r2 in reference to
rs2236007 from the May 2012 EUR panel of 1000 Genomes. The plots were generated using LocusZoom (55). Genome browser views with epigenetic chromatin
features in breast cells (MCF7, HCC1954, MDAMB231, HMEC) on 14q13 are generated using the UCSC genome browser (56). Below is amagnified view of rs12883049
with selected enhancer chromatin marks and DNA sequence of a response element. The gray shading indicates the location of the variant rs12883049.
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At the ER risk region 19p13, variant rs11668840, which is
correlated with the index SNP in Europeans (rs67397200; r2 ¼
0.49), was themost statistically significantly associatedmarker for
ERbreast cancer (OR¼1.25, P¼3.1 108; Supplementary Fig.
S1; Supplementary Tables S4 and S5). The variant rs11668840 is
1.2 kb downstream of the transcription termination site of the
ANKLE1 gene and is not located within any regions of open
chromatin (Supplementary Fig. S2).
Discussion
The majority of GWAS-identified risk variants for breast
cancer are common in women of African ancestry with direc-
tions of effect that are consistent with the discovery popula-
tions. However, in this sample, which is the largest breast
cancer genetics study ever conducted in the women of African
ancestry (6,522 cases and 7,643 controls), only 12 variants were
directionally consistent with previous GWAS and nominally
statistically significant at P < 0.05. In fine-mapping, we were
successful in identifying seven markers for overall breast cancer
or breast cancer subtype in six regions (3p24, 12p11, 14q13,
16q12/FTO, 16q23, 19p13) that were more likely (than the
index variant) to capture the breast cancer association in this
population. In another two regions (11q13 and 16q12/TOX3)
we identified risk variants independent of the index signal.
Among these regions harboring better markers or independent
signals, only at 19p13 was the index variant also significantly
associated with breast cancer risk.
The 74 variants analyzed in this study were reported to have an
average OR of 1.09, with only 17 (23%) havingORs >1.10. Of the
61 SNPs that were directionally consistent with previous GWAS
findings but not statistically significant in African Americans,
statistical power to detect the previously reported effect sizes for
overall breast cancer was 80% for 29 SNPs (48%). While
reasonable statistical power was noted for roughly 50% of these
regions, the inability to achieve statistical significance for the
majority of these loci is likely due to differences in LD structure
between populations of European and African ancestry. Statistical
power in fine-mapping analyses is even more severely limited as
we employed conservative locus-specific alpha levels to limit the
number of false-positive associations. Statistical power to detect
associations as large as those of the index signals while adjusting
for multiple comparisons in the fine mapping was 80% at only
13 of the 70 regions (Supplementary Table S2). It is important to
note that the markers we highlighted in each region only indicate
whether the region replicates in African ancestry populations.
There is a high degree of variability in the association statistics
(ORs, P values and SEs) due tomany factors including genotyping
success rate and imputation quality, which has an impact on the
ranking of associated correlated SNPs.
To further prioritize variants for functional follow-up testing,
we mapped the most strongly associated variants relative to
epigenomic datasets (see Materials and Methods). For the better
markers or independent signals, we identified in this study, 7
overlapped with enhancer histone marks (Supplementary Table
S3). In addition, we discovered that some of the better marker/
independent signals more strongly associated with ERþ breast
cancer were found in ERþ breast cancer-specific enhancers (e.g.,
rs2370946 at 3p24). On the other hand, some of the better
markers or independent signals associated with overall breast
cancer risk (both ERþ and ER) were found in putative breast
enhancers common in both ERþ and ER breast cancer cells (e.g.,
rs609275 in 11q13). The underlying risk variants may play dif-
ferent roles andhaveuniquemechanisms to increase breast cancer
risk; however, we may deduce that subtype-specific enhancer
activity might be tightly linked with some of these risk regions.
The most statistically significant associations in women of
African ancestry identified in both previous studies as well as the
current investigation were with variants on 11q13, 14q13, 16q12/
TOX3, and 19p13 (14, 15). At 11q13, the putative novel signal
locates 53 kb upstream of CCND1 (Cyclin D1). Cyclin D1 plays a
key role in cell-cycle regulation and is one of the most commonly
overexpressed proteins in breast tumors (51). At 14q13, variants
were located in the gene PAX9 (paired box 9), which has been
shown to be required for the growth and survival of breast cancer
cells (52). At 16q12, the signals are located within the intron of a
lncRNA, LINC00918, and the TOX3 (TOX-high mobility group
box family member 3) gene, which may be involved in the
bending and unwinding of DNA and altering chromatin structure
(53). At 19p13, the risk variant is located near the genes BABAM1
(BRISC and BRCA1-A complex member 1), ANKLE1 (Ankyrin
Repeat And LEM Domain-Containing Protein 1), and ABHD8
(abhydrolase domain containing 8). BABAM1 is the best candi-
date that may be influenced by genetic variation in the region
given its interaction with BRCA1 (54).
In conclusion, 54 (73%) of the 74 breast cancer risk variants
examined in women of African ancestry had effects that were
directionally consistent with those previously reported, with 12
being nominally statistically significant. These findings support
prior studies indicating that the majority of established breast
cancer risk loci found in populations of European and Asian
ancestry are also likely to be susceptibility regions for women of
African ancestry. In six regions,weobserved suggestive evidence of
common alleles that may better characterize the association with
breast cancer in women of African ancestry. Despite the sample
size of the current effort, which includes all existing genetic studies
of breast cancer in women of African ancestry globally, substan-
tially larger studies, including multiethnic studies, will be needed
to fully understand the genetic architecture of breast cancer in
women of African ancestry.
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